Page last updated: 2024-08-18

2-aminopyrimidine and Benign Neoplasms

2-aminopyrimidine has been researched along with Benign Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Aoki, Y; Fukami, TA; Hasegawa, K; Kim, SJ; Miura, T; Na, YJ; Ono, N; Shimma, N; Shindo, H; Shiratori, Y; Suda, A; Tsukuda, T; Yoon, DO	1
Bhandare, RR; Bloukh, SH; Edis, Z; Jadhav, M; Khan, TA; Sankhe, K	1
Chen, K; Dong, Y; Han, Y; Li, Y; Liu, Y; Luo, Y; Qin, M; Wang, C; Xu, L; Ye, T; Zhao, Y	1

Reviews

1 review(s) available for 2-aminopyrimidine and Benign Neoplasms

Article	Year
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors. Molecules (Basel, Switzerland), 2021, Aug-26, Volume: 26, Issue:17 Topics: Animals; Antineoplastic Agents; Aurora Kinases; Cell Cycle; Cell Cycle Proteins; Drug Discovery; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines	2021

Article

Year

Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.

Molecules (Basel, Switzerland), 2021, Aug-26, Volume: 26, Issue:17

Topics: Animals; Antineoplastic Agents; Aurora Kinases; Cell Cycle; Cell Cycle Proteins; Drug Discovery; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines

2021

Other Studies

2 other study(ies) available for 2-aminopyrimidine and Benign Neoplasms

Article	Year
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Escherichia coli; HSP90 Heat-Shock Proteins; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Reproducibility of Results; Structure-Activity Relationship; Surface Plasmon Resonance; Triazines; Xenograft Model Antitumor Assays	2011
Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. European journal of medicinal chemistry, 2019, Nov-01, Volume: 181 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Molecular Docking Simulation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2019

Article

Year

Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.

Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19

Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Escherichia coli; HSP90 Heat-Shock Proteins; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Reproducibility of Results; Structure-Activity Relationship; Surface Plasmon Resonance; Triazines; Xenograft Model Antitumor Assays

2011

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.

European journal of medicinal chemistry, 2019, Nov-01, Volume: 181

Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Molecular Docking Simulation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2019